Interview with Mark Fladrich, Managing Director, Australia & New Zealand,…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
Address: 5 Alma Road, North Ryde NSW 2113,Australia
Tel: +61 2 9978 3500
Web: http://www.astrazeneca.com.au/home/
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians.
AstraZeneca is one of Australia’s largest private sector investors in medical research and development (R&D) and has, invested more than $250 million in Australia in the last decade.
It is the largest national manufacturer of pharmaceuticals in Australia, providing $1.2 billion of medicines to the local market and $200 million in exports.
AstraZeneca currently involved in more than 50 clinical trials at over 200 sites across Australia, investigating potential new treatments in the areas of oncology, cardiovascular, diabetes, infection, gastrointestinal, neuroscience, respiratory, and inflammation.
The company employs more than 900 people in Australia and is committed to being recognised as an ‘Employer of Choice’.
AstraZeneca couples a global reach with local knowledge that stems from its long heritage in Australia that dates back to 1957.
AstraZeneca focuses on the following health care areas: cardiovascular, diabetes, gastrointestinal, neuroscience, oncology, respiratory, anaesthesia and pain management.
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
See our Cookie Privacy Policy Here
